$IMNN Check $CORT ROSELLA – Pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in 381 patients with platinum-resistant ovarian cancer – Both dual primary endpoints (progression-free and overall survival) met – Results published in The Lancet (Lorusso et al, April 2026) FD

stocktwits · 2026-08-20 · Bullish AI sentiment

$CORT $IMNN

Read the original at stocktwits ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.